Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
Search
 
My Lists

Codexis  (Stock symbol: CDXS )

200 Penobscot Drive
Redwood City, CA 94063
USA
650.421.8100
Website Company Summary Management Team
Board

Outside board: (May no longer be on the board) Dennis P Wolf (MySQL CFO) Byron L Dorgan (United States Senate Former Senator) David V Smith (IntegenX COO) Patrick Y Yang (Genentech EVP Product Operations) Pam P Cheng (MSD China President) Thomas R Baruch (Presidio Partners) Bernard J Kelley (Merck Manufacturing Former Division President)
Advisory board: William Hazeltine (Haseltine Associates CEO) Davinder Brar (Ranbaxy Laboratories Former CEO) Ian Cunningham (GSK);  Burton Rein (Cambrex);  Joseph Renner (Geneva Pharmaceuticals);  Mike Edinberry (Pfizer);  David Agger (NSC Technologies);  Arnold Demain (Drew University);  David Dodds (Bristol-Myers Squibb);  Ian Fotheringham (NutraSweet);  Gerhard Mayr (Eli Lilly EVP Operations) Peter Pollak (Lonza);  Roger Sheldon (Delft University of Technology)
Former outside board: Daniel Wang (Massachusetts Institute of Technology);  Patrick G Enright (Longitude Capital Managing Director) Bruce A Pasternack (Special Olympics Former President/CEO) Bill Rothwell (Shell Global Solutions VP) Alexander Karsner (Manifest Energy CEO) Chris Steng (Royal Dutch Shell VP Finance) James Sulat (Maxygen CFO) Mun Yew Wong (EDB Investments Director of Investments) Byron Corgan (U.S. Senator from North Dakota former) Pedro I Mizutani (Raízen Energia Participacoes Division EVP) Lawrence W Briscoe (Maxygen) Simba Gill (Maxygen);  Russell J Howard (Maxygen)
Company

Business description: Codexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver® platform to discover and develop novel, high performance enzymes and novel biotherapeutics. Codexis enzymes have applications in the sustainable manufacturing of pharmaceuticals, food, and industrial products; in the creation of the next generation of life science tools; and as gene therapy and biologic therapeutics. The Company’s unique performance enzymes drive improvements such as: reduced energy usage, waste generation and capital requirements; higher yields; higher fidelity diagnostics; and more efficacious therapeutics. Codexis enzymes enable the promise of synthetic biology to improve the health of people and the planet.
Partners include: ChevronEli LillyAndCo.Pfizer ;  Cargill Dow;  DSM;  Hercules;  Matrix Laboratories;  MerckAndCo. ;  Novozymes;  Rio Tinto;  Royal Dutch Shell ;  Sandoz;  Schering-Plough ;  Shasun Chemicals and Drugs;  Teva ;  Teva Pharmaceutical Industries
Capital

Rounds: 4
Recent Fundings: Jul 2004   Oct 2002
Capital raised: 80.0M
Last Round: 37.0M
Ownership: Public   Ipo Filing
Stock Symbol: CDXS
Corporate investors: MaxygenPfizer;  ChevronTexaco Venture Equities

Last Tweets


 

Last Mentions


Overview
Record updated: Jul 2022
Sector: Medical Devices & Diagnostics
Year Founded: 2002
Headcount: 301-400 as of Jul 2022
Rounds: 4
Recent Fundings: Jul 2004   Oct 2002
Capital Raised: 80.0M
Last Round: 37.0M
Ownership: Public   Ipo Filing
Stock Symbol: CDXS